A Retrospective Multicenter Analysis of PD-L1 expression in Japanese Renal Cell Carcinoma patients
Not Applicable
- Conditions
- renal cell carcinoma
- Registration Number
- JPRN-UMIN000034131
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
American Association for Cancer Research Annual Meeting 2020
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 830
Inclusion Criteria
Not provided
Exclusion Criteria
1.Malignancies other than RCC is co-existed during the time from nephrectomy and death. 2.Treatment with anti-CTLA-4 antibody, anti-PD-1/PD-L1 antibodies as first-line therapy for recurrent or metastatic RCC.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OS in PD-L1 negative (IC0) and positive (IC1/2/3) patients. OS is defined as the time from the initiation date of first line treatment to death due to any cause.
- Secondary Outcome Measures
Name Time Method 1.OS in each level of PD-L1 expression(IC0, IC1,IC2,IC3), OS is defined as the time from the initiation date of first line treatment to death due to any cause. 2.OS defined as the time from initial nephrectomy includes receiving cytoreductive nephrectomy to death due to any cause in PD-L1negative and positive patients. 3.Time to relapse after radical nephrectomy 4.Treatment duration of first line and second line.